DEB025/alisporivir and ribavirin in chronic hep C genotype 2/3

• Research type

  Research Study

• Full title

  A multicenter, open-label, randomized, 3-arm, phase II profiling trial of pharmacokinetics, pharmacodynamics and safety of DEB025/Alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 treatment naïve patients

• IRAS ID

  135910

• Contact name

  Alison Levoguer

• Contact email

  alison.levoguer@novartis.com

• Sponsor organisation

  Novartis Pharmaceuticals Corporation

• Eudract number

  2012-004185-17

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  13/SC/0463

• Date of REC Opinion

  16 Oct 2013

• REC opinion

  Further Information Favourable Opinion